Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

December 07, 2023 By The ASCO Post Staff

Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).

Related Content